U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)				
As the below nar	ned inventor(s), I/we declare that:			
This declaration	is directed to:			
	☐ The attached application, or			
	Application No, filed on			
	as amended on (if applicable);			
I/we believe that I/ sought;	we am/are the original and first inventor(s) of the subject matter which is claim	ned and for which a patent is		
	d and understand the contents of the above-identified application, including th ically referred to above;	e claims, as amended by any		
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.				
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.				
Full Name of In	ventor(s)			
inventor 1	WADE STANTON BLAIR			
Signature	Weels Rome Citizen of	US		
Inventor 2	JOAN QUN CAO			
Signature	Citizen of	CANADA		
Inventor 3	JASON ISAACSON			
Signature	Citizen of	us		
Inventor 4	AMY KAREN PATICK			
Signature	Ciny karen Patch Citizen of	US		
Additional inventors are being named on				

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** To be assigned Herewith **Filing Date First Named Inventor** WADE STANTON BLAIR DUAL ASSAY FOR EVALUATING ACTIVITY AND CYTOTOXICITY OF COMPOUNDS IN POWER OF ATTORNEY Title THE SAME POPULATION OF CELLS; IMPROVED LUCIFERASE GENES AND **CORRESPONDENCE ADDRESS USES THEREOF** INDICATION FORM **Art Unit** To be assigned To be assigned **Examiner Name Attorney Docket Number** PC25522A I hereby appoint: 28940 Practitioners at Customer Number M Practitioners named below: Registration Number Name as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith. Please recognize or change the correspondence address for the above-identified application to: The above-mentioned Customer Number. \boxtimes OR The address associated with Customer Number OR Firm or Individual Name Address Address State Zip City Country Fax Telephone I am the: Applicant/Inventor. \mathbb{N} Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). SIGNATURE of Applicant or Assignee of Record **WADE STANTON BLAIR** Name Signature 4103 NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and

forms if more than one signature is required, see below*. forms are submitted.

☐ *Total of

To be assigned

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Application Number

		<u> </u>			 :-		
POWER OF ATTORNEY and CORRESPONDENCE ADDRESS		Filing Da	Filing Date		Herewith		
		First Named Inventor		JOAN C	JOAN QUN CAO		
		Title	Title		DUAL ASSAY FOR EVALUATING ACTIVITY AND CYTOTOXICITY OF COMPOUNDS IN THE SAME POPULATION OF CELLS; IMPROVED LUCIFERASE GENES AND USES THEREOF		
INDICATION	ON FORM	Art Unit	Art Unit		To be assigned		
		Examine	er Name	To be a	To be assigned		
		Attorney	Docket Number	PC255	PC25522A		
I hereby appoint:	<u> </u>						
	mor Number	2894	10				
Practitioners at Custor OR	nei Numbei	207-					
Practitioners named be	elow:						
	Name		Reaist	ration Num	ion Number		
							
		_					
4 44 42 42	-1/-> 4	:-!	abarra and to trans	ant all			
as my/our attorney(s) or age business in the United States	nt(s) to prosecute the applications S Patent and Trademark Office	connected t	above, and to trans herewith.	act an			
Please recognize or change	the correspondence address for	or the above	-identified applicati	on to:			
The above-mentioned							
OR	Customer Number.						
OR .			·				
The address associated with Customer Number							
OR .							
Firm or Individual Name				,			
Address							
Address	17.77						
City			State	Zip			
Country							
Telephone		Fa	ах				
I am the: Applicant/Inventor.							
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).							
SIGNATURE of Applicant or Assignee of Record							
Name JOAN QUN CAO							
Signature	Signature / / /						
Date 11/04 Po3							
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.							
☐ *Total of forms are submitted.							

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and

To be assigned

JASON ISAACSON

Herewith

Zip

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Filing Date

Titie

POWER OF ATTORNEY

Address City

Country

X

Name

Date

*Total of

Signature

Telephone I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

JASON ISAACSON

Nov

forms if more than one signature is required, see below*.

forms are submitted.

Application Number

First Named Inventor

DUAL ASSAY FOR EVALUATING ACTIVITY AND CYTOTOXICITY OF COMPOUNDS IN THE SAME POPULATION OF CELLS; **CORRESPONDENCE ADDRESS** IMPROVED LUCIFERASE GENES AND **USES THEREOF** INDICATION FORM **Art Unit** To be assigned **Examiner Name** To be assigned **Attorney Docket Number** PC25522A I hereby appoint: Practitioners at Customer Number 28940 OR Practitioners named below: Name **Registration Number** as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith. Please recognize or change the correspondence address for the above-identified application to: \bowtie The above-mentioned Customer Number. OR The address associated with Customer Number OR Firm or Individual Name Address

State

Fax

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple

SIGNATURE of Applicant or Assignee of Record

2003

To be assigned

PTO/SB/81(06-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number

		Filing D	Filing Date		Herewith		
			First Named Inventor		AMY KAREN PATICK		
POWER OF ATTORNEY and CORRESPONDENCE ADDRESS		Title	Title		DUAL ASSAY FOR EVALUATING ACTIVITY AND CYTOTOXICITY OF COMPOUNDS IN THE SAME POPULATION OF CELLS; IMPROVED LUCIFERASE GENES AND USES THEREOF		COMPOUNDS IN OF CELLS;
INDICAT	ION FORM	Art Unit			To be ass		
		Examin	Examiner Name		To be assigned		
		Attorne	Attorney Docket Number		PC25522A		
I hereby appoint:							
Practitioners at Customer Number OR		2894	28940				
Practitioners named	below:						
	Name		Registration Number				
,							
as my/our attorney(s) or ag business in the United State	ent(s) to prosecute the applica es Patent and Trademark Offic	ition identified se connected t	above, and	d to transact	all	•	
Please recognize or change	e the correspondence address	for the above	-identified	application to	o:		
The above-mentioned Customer Number. OR							
The address associated with Customer Number OR							
Firm or individual Name							
Address					-		
Address							
City		s	tate		Zip		
Country			-	·			
Telephone		Fa	×				
I am the:							
Applicant/Inventor.							
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).							
SIGNATURE of Applicant or Assignee of Record							
Name AMY KAREN PATICK							
Signature	Signature amy karen Patich						
Date 11-4-03							
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.							
*Total of forms are submitted.							

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and



Son Prop

MAY 30, 2003

PTAS

PFIZER, INC. JEFFREY W. RENNECKER 10777 SCIENCE CENTER DRIVE SAN DIEGO, CA 92121 Under Secretary of Commerce For Intellectual Property and Director of the United States Patent and Trademark Office Washington, DC 20231 www.uspto.gov



102350433A

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 01/28/2003

REEL/FRAME: 013690/0764

NUMBER OF PAGES: 5

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

BLAIR, WADE STANTON

DOC DATE: 01/13/2003

ASSIGNOR:

CAO, JOAN

DOC DATE: 01/13/2003

ASSIGNOR:

ISAACSON, JASON

DOC DATE: 01/13/2003

ASSIGNOR:

PATICK, AMY KAREN

DOC DATE: 01/13/2003

ASSIGNEE:

AGOURON PHARMACEUTICALS, INC. PATENT PATENT 10777 SCIENCE CENTER DRIVE SAN DIEGO, CALIFORNIA 92121

ASSIGNEE:

PFIZER, INC. 235 EAST 42ND STREET NEW YORK, NEW YORK 10017 013690/0764 PAGE 2

SERIAL NUMBER: 60429382

PATENT NUMBER:

FILING DATE: 11/25/2002

ISSUE DATE:

PAULA MCCRAY, EXAMINER ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS



01-29-2003





`		
		100050400
Form PTO-1595	RECORD.	102350433
Day (02)	ILLICORDA.	

U.S. DEPARTMENT OF COMMERÇE Patent and Trademark Office Box ASSIGNMENTS

	ÒM	B No 0651-0011 (exp. 4/94) PATENTS	ONLY Box ASSIGNMENTS		
		To the Honorable Commissioner of Patents and Trademarks:	Please record the attached original document(s) or copy thereof.		
	1.	Wade Stanton Blair; Joan Cao; Jason Isaacson: Amy Karen Patick	Name and address of receiving party(ies): Name: Agouron Pharmaceuticals, Inc. Internal Address: Patent Department		
	3.	Mature of Conveying party(ies) attached?	Street Address: 10777 Science Center Drive City: San Diego State: CA ZIP 92121 Additional name(s) & address(es) attached Yes No		
ý	4.	Application number(s) or patent number(s): If this document is being filed together with a new application A. Patent Application No.(s) 60/429,382 Additional numbers attached	B. Patent No.(s)		
	5.	Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved: 1		
		Name: Jeffrey W. Rennecker Internal Address: Pfizer, Inc. Street Address: 10777 Science Center Drive	7. Total fee (37 CFR 3.41)		
		City: San Diego State: CA ZIP: 92121	8. Deposit account number:		
DO NOT USE THIS SPACE					
	9.	To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Jeffrey W. Rennecker (Reg. 40,784) January 21, 2003 Name of Person Signing Signature Date Total number of pages including cover sheet, attachments, and document: 4			
L	/	•			

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents & Trademarks, Box Assignments

₹29/2003 LMUELLER 00000055 500329 60429382

Washington, D.C. 20231

01 FC:8021

(Rev. 6-93)

40.00 CH

2. Name of receiving party(ies): (Continued)

Pfizer Inc.

Street Address: 235 East 42nd Street

City: New York State: NY ZIP: 10017

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged, we, Wade Stanton Blair of 1022 Cima Drive, San Marcos, CA 92069; Joan Cao of 6115 Paseo Jaquita, Carlsbad CA, 92009; Jason Isaacson of 11275 Affinity Court. #120, San Diego, CA 92131; and Amy Karen Patick of 2239 Cortina Circle, Escondido, CA 92029-5545, respectively, hereby sell, assign and transfer unto AGOURON PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of California, United States of America, and having a place of business at 10777 Science Center Drive, San Diego, California 92121, United States of America, our entire right, title and interest, except as limited herein below, in and to provisional patent application of the United States of America, having PFIZER INC. Docket No. PC25522US, entitled "DUAL ASSAY FOR EVALUATING ACTIVITY AND CYTOTOXICITY OF COMPOUNDS IN THE SAME POPULATION OF CELLS," filed in the United States Patent and Trademark Office on November 25, 2002 and assigned application number 60/429,382, and our entire right, title and interest, in the United States of America, in and to all our inventions, whether joint or sole, disclosed in said patent application; and our entire right, title and interest in and to all applications filed in the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted in the United States of America on the foregoing applications;

and we hereby sell, assign and transfer unto PFIZER INC., a corporation organized and existing under the laws of the State of Delaware, United States of America, and having a place of business at 235 East 42nd Street, New York, New York 10017, United States of America, our entire right, title and interest, in all countries of the world except the United States of America, in and to all our inventions, whether joint or sole, disclosed in said provisional patent application; and our entire right, title and interest in and to all patent applications filed outside the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted outside the United States of America on said patent applications filed outside the United States of America; and the right to claim priority from said provisional patent application under

the Paris Convention for the Protection of Industrial Property, and under any and all other such treaties and agreements to which the United States of America is a party and which afford similar priority-claiming privileges, in all countries of the world except the United States of America;

and we hereby agree, whenever requested, to communicate to said AGOURON PHARMACEUTICALS, INC. and said PFIZER INC., and their successors and assigns, any facts known to us respecting said inventions, to testify in any legal proceeding respecting said inventions, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in all countries of the world.

Signed and witnessed this	day of Jan. 2003 at		
San Digo CA USA			
J	11000		
	Wal \$18		
	Wade Stanton Blaif		
In the presence of:			
Doneill Digon)		
Danielle Dixon			
[print name here, sign above]			
	Jan.		
Signed and witnessed this 13	day of 2003 at		
San Diego, CA,	usA.		
	enj		
	Joan Cao		
In the presence of:	•		
Danille Dyon			
Danielle Dixon			
[print name here, sign above]			

Signed and witnessed this 13	th day of January, 2003 at				
San Diego	, CA USA				
3 -					
	Jason Isaaoson				
In the presence of:					
Eanille Dyon					
[print name here, sign above]					
Signed and witnessed this	A USA January 2003 at				
San Diego, C	A USA				
V	Amy Karen Patick				
	Amy Karen Patick				
In the presence of:					
SI	2				
Jules Beardsleig	ン 				
[print name here, sign above]					